XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.

XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.
B
B

Biogen

Haberler

Reuters - 5 gün önce

U.S. STOCKS Revance Therapeutics, Insulet, StepStone

BUZZ-U.S. STOCKS ON THE MOVE-Revance Therapeutics, Insulet, StepStone Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes swung between gains and losses on the last day of a tumultuous week that rocked the global markets as the low-yielding yen surged and fears of a recession gripped the world's biggest economy.
A
B
B
E
I
N
L
T
U
U
Reuters - 5 gün önce

Biogen-Eisai's Alzheimer drug sales back to 'good growth momentum' - Jefferies

BUZZ-Biogen-Eisai's Alzheimer drug sales back to 'good growth momentum' - Jefferies ** Brokerage Jefferies says Biogen BIIB.O and Eisai's 4523.T Alzheimer's drug Leqembi earned $13.5 mln in sales in July, citing healthcare data and analytics firm Symphony ** The $3 mln month-over-month increase may suggest Leqembi is back to good growth momentum af
B
Reuters - 1 hafta önce

U.S. Actinium, Albemarle, ArcBest

U.S. RESEARCH ROUNDUP- Actinium, Albemarle, ArcBest Aug 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Actinium Pharmaceuticals, Albemarle and ArcBest, on Tuesday. HIGHLIGHTS * Actinium Pharmaceuticals Inc ATNM.A : JonesTrading cuts PT to $9 from $26 * Albemarle ALB.N : Baird cuts to neutral; cuts target price to $85 from $102 * ArcBest Corp ARCB.O : Stephens cuts target price to $130 from $145 * Crispr Therapeuti
A
A
B
B
C
C
C
C
D
Reuters - 2 hafta önce

Street View: Patience needed to see Biogen's steady growth

BUZZ-Street View: Patience needed to see Biogen's steady growth ** Biogen BIIB.O lifted its annual profit forecast on Thursday due to cost cuts and better-than-expected sales of its various treatments, even as the U.S. adoption of its Alzheimer's drug remains slow ACQUISITIONS NEEDED TO BUILD OUT ITS PORTFOLIO ** Needham ("Buy", PT $285) says "still need patience before we see an inflection point" ** Jefferies ("Buy", PT $250) says more business development deals likely to go beyond Alzheimer's
B
Reuters - 2 hafta önce

U.S. Apple, Centerpoint Energy, Cummins

U.S. RESEARCH ROUNDUP-Apple, Centerpoint Energy, Cummins Aug 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Apple, Centerpoint Energy and Cummins, on Friday. HIGHLIGHTS * Apple Inc AAPL.O : Wedbush raises target price to $285 from $275 * Centerpoint Energy CNP.N : JP Morgan cuts to neutral from overweight * Cummins CMI.N : Jefferies raises target price to $365 from $345 * Motorola MSI.N : JP Morgan raises target pr
A
A
B
B
I
K
M
A
B
C
A
A
A
A
C
C
L
M
Reuters - 2 hafta önce

U.S. STOCKS Spirit Airlines, Labcorp, Air Products and Chemicals

BUZZ-U.S. STOCKS ON THE MOVE-Spirit Airlines, Labcorp, Air Products and Chemicals Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes fell over 1% on Thursday, bogged down by megacap tech and chip stocks, while small-caps bore the brunt of selling pressure as weak manufacturing data renewed concerns around a slowdown in the U.S.
B
I
J
Q
W
C
U
U
A
B
F
L
T
Reuters - 2 hafta önce

Biogen Inc reports results for the quarter ended in June - Earnings Summary

Biogen Inc reports results for the quarter ended in June - Earnings Summary Biogen Inc BIIB.OQ reported quarterly adjusted earnings of $5.28​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $4.02. The mean expectation of twenty nine analysts for the quarter was for earnings of $4.03 per share.
B
Reuters - 2 hafta önce

U.S. STOCKS Qualcomm, Moderna, Hershey

BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Moderna, Hershey Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Futures tied to Wall Street's main indexes kicked off August on a high note, boosted by the Federal Reserve's signals of a September rate cut and a rosy sales forecast from Meta, while a pullback in some megacap and chip stocks kept gains in check.
B
I
Q
U
P
Reuters - 2 hafta önce

U.S. STOCKS Meta, Eli Lilly, Hershey

BUZZ-U.S. STOCKS ON THE MOVE-Meta, Eli Lilly, Hershey Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Futures tied to Wall Street's main indexes kicked off August on a high note, boosted by the Federal Reserve's signals of a September rate cut and a rosy sales forecast from Meta, while a pullback in some megacap and chip stocks kept gains in check.
B
I
Q
U
Reuters - 2 hafta önce

Eisai Co Ltd- Global Revenue Of Leqembi In 1Q Of Fiscal 2024 Was 6.3 Billion Yen, Approx. 2.2 Times Higher Than In Previous Quarter

BRIEF-Eisai Co Ltd- Global Revenue Of Leqembi In 1Q Of Fiscal 2024 Was 6.3 Billion Yen, Approx. 2.2 Times Higher Than In Previous Quarter Aug 1 (Reuters) - Eisai Co Ltd 4523.T : EISAI CO LTD- GLOBAL REVENUE OF LEQEMBI IN 1Q OF FISCAL 2024 WAS 6.3 BILLION YEN, APPROX. 2.2 TIMES HIGHER THAN IN THE PREVIOUS QUARTER Source text for Eikon: ID:nTSta88ebd
B
Reuters - 2 hafta önce

Biogen gains on lifting annual profit forecast

BUZZ-Biogen gains on lifting annual profit forecast ** Shares of biopharmaceutical firm Biogen BIIB.O rise ~1% to $215.03 premarket ** Co raises 2024 adjusted profit forecast to $15.75-$16.25 per share, from $15-$16, betting on the launch of new treatments and a cost-cutting program ** Analysts were expecting annual adj EPS of $15.58 - LSEG data **
B
Reuters - 2 hafta önce

Biogen lifts profit forecast, signals progress in turnaround effort

UPDATE 2-Biogen lifts profit forecast, signals progress in turnaround effort Adds CEO comment in paragraph 3 and analyst comment in paragraph 11 By Manas Mishra and Mariam Sunny Aug 1 (Reuters) - Biogen BIIB.O lifted its full-year profit forecast on Thursday due to cost cuts and better-than-expected sales of its various treatments, even as the U.S.
B
N
Reuters - 2 hafta önce

Biogen Q2 Adjusted EPS USD 5.28 Vs. IBES Estimate USD 4.03

BRIEF-Biogen Q2 Adjusted EPS USD 5.28 Vs. IBES Estimate USD 4.03 Aug 01 (Reuters) - Biogen Q2 EPS USD 4. Q2 revenue USD 2,500 million vs. IBES estimate USD 2,382 million
B
Reuters - 2 hafta önce

Biogen lifts 2024 profit forecast on hopes of new product launches

Biogen lifts 2024 profit forecast on hopes of new product launches Aug 1 (Reuters) - Biogen BIIB.O lifted its full-year earnings forecast on Thursday, as the launch of new treatments such as rare disease drug Skyclarys is expected to make up for a market-share loss of its older multiple sclerosis medicines. The drugmaker has cut jobs, bolstered its pipeline for rare disease medicines through takeover deals and unveiled new products, such as Alzheimer's disease drug Leqembi as part of its plan to
B
N
Reuters - 2 hafta önce

Biogen Reports Q2 Adjusted EPS $5.28 Versus Ibes Estimate $4.03

BRIEF-Biogen Reports Q2 Adjusted EPS $5.28 Versus Ibes Estimate $4.03 Aug 1 (Reuters) - Biogen Inc BIIB.O : BIOGEN Q2 ADJUSTED EPS $5.28 VERSUS IBES ESTIMATE $4.03 BIOGEN Q2 REVENUE $2.47 BILLION VERSUS IBES ESTIMATE $2.38 BILLION BIOGEN: TO RETAIN BIOSIMILARS BUSINESS BIOGEN OUTLOOK FY REVENUE TO DECLINE BY A LOW-SINGLE DIGIT PERCENTAGE; IBES ESTI
B
Reuters - 2 hafta önce

Fed nods to cut, chips rebound, BoE up next

MORNING BID AMERICAS-Fed nods to cut, chips rebound, BoE up next A look at the day ahead in U.S. and global markets from Mike Dolan The Federal Reserve left Wall Street with little doubt about a first U.S. interest rate cut in seven weeks' time, but multiple cross-currents from the earnings season , Japan and China, and domestic politics all make for a noisy start to August.
A
A
A
B
C
G
I
N
R
U
X
M
J
U
U
U
F
E
W
A
M
Reuters - 2 hafta önce

What to Watch in the Day Ahead - Thursday, August 1

What to Watch in the Day Ahead - Thursday, August 1 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Apple is expected to report a rise in third-quarter revenue, helped by higher iPad sales from new launches and strength in its services business.
A
A
B
C
I
K
V
M
B
Reuters - 2 hafta önce

Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest

Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest By Julie Steenhuysen CHICAGO, July 30 (Reuters) - The benefit of Eisai 4523.T and Biogen's BIIB.O Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data presented at an Alzheimer's meeting on Tuesday.
B
Reuters - 2 hafta önce

Biogen Says Co, Beckman Coulter And Fujirebio To Collaborate On Blood-Based Biomarkers And Test For Tau Pathology In Alzheimer’S Disease

BRIEF-Biogen Says Co, Beckman Coulter And Fujirebio To Collaborate On Blood-Based Biomarkers And Test For Tau Pathology In Alzheimer’S Disease July 30 (Reuters) - Biogen Inc BIIB.O : BIOGEN, BECKMAN COULTER AND FUJIREBIO TO COLLABORATE ON BLOOD-BASED BIOMARKERS AND TEST FOR TAU PATHOLOGY IN ALZHEIMER’S DISEASE BIOGEN INC: WILL PROVIDE ALZHEIMER
B
Reuters - 2 hafta önce

Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug

Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug TOKYO, July 29 (Reuters) - Shares of Japan's Eisai 4523.T tumbled 11% and were on track for their biggest one-day fall in three years on Monday, after the European Union's regulator rejected the drugmaker's Leqembi treatment for early Alzheimer's disease. The EU drugs regulator last week said the risk of serious brain swelling did not outweigh the drug's small impact on slowing cognitive decline.
B
U

Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Risk uyarısı: Sermayeniz risk altında. Kaldıraçlı ürünler herkese uygun olmayabilir. Lütfen Risk Bildirimi'mizi dikkate alın.